Pharmaceuticals, Biotechnology & Life Sciences

Beijing Tongrentang poised to profit from 2026 TCM policy upgrades, expanding core drug list and quality standards, boosting earnings and market position.

Discover how GC CELL CORP, a Korea Exchange-listed biotech leader, drives sustainable health‑care innovation in South Korea with transparent growth and cutting‑edge solutions.

Amgen (AMGN) stays strong amid a soft Nasdaq‑100: a biotech leader with a $217.66 bn cap and 24.97 PE, trading inside its 52‑week range on Oct 7.

Inside Roivant Sciences’ latest insider trades: director Melissa Epperly buys, sells, and options 17,750 shares—learn the moves, price swings, and what it means for the company’s biotech future.

Haleon PLC outpaces a falling FTSE 100, proving resilient in a high‑oil, high‑yield market—why investors should re‑examine this steady consumer‑health growth.

Menovo’s soaring P/E and stock volatility reveal hidden risks in China’s pharma sector—why investors should scrutinize its future prospects.

Galderma’s long‑term Nemluvio study shows sustained itch relief and lesion reduction in atopic dermatitis, confirming its safety and boosting investor confidence.

How Cytokinetics’ executive stock moves hint at a bullish outlook for its muscle‑modulating biotech pipeline.

Valneva revokes UK approval for IXCHIQ® travel vaccine, yet retains global authorisations and strong portfolio, signalling limited financial impact.

Hemostemix Inc. battles financial turbulence while advancing blood‑derived cell therapies for severe disorders—investors watch its risky biotech comeback.